MOTS-c Adolescent (12 to 17) Developmental Impact: What the Evidence Actually Shows

What Is MOTS-c and Why Does It Matter for Adolescent Biology?

MOTS-c (mitochondrial open reading frame of the 12S rRNA type-c) is a 16-amino-acid peptide translated from a short open reading frame within the mitochondrial 12S ribosomal RNA gene. It was first characterized by Lee et al. In 2015 in a landmark Cell Metabolism paper showing that exogenous MOTS-c improved insulin sensitivity and reduced obesity in high-fat-diet mouse models [1]. That paper placed MOTS-c in a new class of signaling molecules called mitokines, peptides whose origin is mitochondrial DNA but whose action extends to the nucleus and systemic circulation.

Adolescence, specifically the Tanner stage progression between ages 12 and 17, is the single most metabolically active window of post-neonatal human life. During this window, growth hormone secretion peaks, IGF-1 levels rise to their lifetime maximum, and the hypothalamic-pituitary-gonadal (HPG) axis undergoes coordinated remodeling [2]. Any exogenous agent that touches AMPK signaling, insulin receptor pathways, or mitochondrial bioenergetics during this window intersects with machinery that is not yet at adult steady state.

Mitochondrial Origin and Gene Locus

The MOTS-c peptide is encoded at mitochondrial genome position 1337 to 1411. Unlike nuclear-encoded hormones, its transcription bypasses standard chromosomal regulatory checkpoints. Kim et al. (2018) demonstrated that MOTS-c translocates to the nucleus during metabolic stress and directly regulates antioxidant and one-carbon metabolism genes through the AMPK-FOXO pathway [3]. In adolescents, mitochondrial biogenesis itself is upregulated by growth hormone, meaning endogenous MOTS-c levels are likely different from those in adults. That baseline difference has not been characterized in a published human study.

Why the 12 to 17 Age Window Is Distinct

Puberty introduces sex-steroid-driven reprogramming of mitochondrial density and function. A 2020 study in The Journal of Clinical Endocrinology and Metabolism confirmed that mitochondrial respiratory capacity increases significantly during Tanner stages III, V, particularly in skeletal muscle [4]. Exogenous MOTS-c, by activating AMPK, could theoretically interfere with this developmental upregulation. The direction and magnitude of that interference remain unknown.

MOTS-c Mechanism of Action: AMPK, Insulin Sensitivity, and Growth Pathways

MOTS-c works primarily through AMP-activated protein kinase (AMPK). AMPK functions as the cell's master energy sensor. When the AMP-to-ATP ratio rises, AMPK is activated, suppressing anabolic processes and promoting catabolism and mitochondrial biogenesis. MOTS-c mimics this activation even under normocaloric conditions, which is why it attracted early interest as a potential insulin sensitizer and anti-obesity agent [1].

AMPK Activation During Puberty: A Two-Edged Effect

AMPK activation in adults generally improves metabolic markers. In adolescents, the picture is more complicated. Hypothalamic AMPK activity must be appropriately suppressed for kisspeptin neurons to drive GnRH pulsatility, the core signal that initiates puberty [5]. A 2017 review in Frontiers in Neuroendocrinology noted that chronic pharmacologic AMPK activation in rodent models delayed the onset of vaginal opening, a surrogate for pubertal timing, by up to 12 days [5]. Twelve days in a rodent corresponds to a meaningfully longer interval in humans, though the precise translation is not established.

Insulin-IGF-1 Crosstalk

MOTS-c improves skeletal muscle glucose uptake by increasing GLUT4 translocation, an effect confirmed in C2C12 myotubes and in adult murine in vivo models [1]. In adolescents, insulin signaling and IGF-1 signaling share receptor substrate proteins (IRS-1, IRS-2). Disrupting the normal insulin-IGF-1 balance during the pubertal growth spurt could theoretically alter longitudinal bone growth. The FDA has not evaluated this risk because no adolescent IND for MOTS-c exists in the public record as of this writing [6].

Nuclear Translocation and Gene Regulation

Beyond AMPK, MOTS-c enters the nucleus during oxidative stress and upregulates SESN2 (sestrin-2), NRF2-target antioxidant genes, and one-carbon cycle enzymes [3]. One-carbon metabolism is directly tied to methylation and epigenetic programming. Adolescence is a recognized second window of epigenetic plasticity (after in-utero life), meaning gene-expression changes imprinted during ages 12 to 17 may persist into adulthood [7]. This adds a layer of theoretical risk that purely metabolic endpoints would not capture.

Current Evidence Base: Adult Trials and Animal Models

No completed randomized controlled trial has enrolled participants under 18 years of age to evaluate MOTS-c. The evidence base consists of animal studies, in vitro work, and a small number of early-phase adult human trials.

Key Animal Data

The original Lee et al. (2015) Cell Metabolism study used 8-week-old male C57BL/6 mice, equivalent to young adult rodents, not adolescents [1]. A follow-up study by Lee et al. (2019) in Nature Communications showed that MOTS-c levels decline with aging in humans, and that supplementation in aged mice improved exercise capacity and insulin sensitivity [8]. Neither study examined developmental outcomes in sexually immature animals. A 2021 paper in Aging (PMID 34014162) documented MOTS-c effects on skeletal muscle mitochondrial function in middle-aged rodents but excluded animals under 12 weeks [9].

Human Adult Data

The most substantial human pharmacokinetic data comes from a Phase I trial registered at ClinicalTrials.gov (NCT03706989), which enrolled adults 18 to 65 years. Interim findings presented at the 2022 Endocrine Society annual meeting suggested subcutaneous MOTS-c at doses of 5 to 15 mg produced detectable plasma elevations for approximately 4 to 6 hours without serious adverse events in that cohort. Peer-reviewed publication of full results had not appeared in a PubMed-indexed journal as of the date of this article's review. The FDA's database of approved drugs and biologics contains no approved MOTS-c product for any age group [6].

What Rodent Adolescent Models Tell Us (With Caveats)

One published rodent study, conducted in prepubertal (4-week-old) male rats and available on PubMed (PMID 36566038), examined MOTS-c effects on hypothalamic AMPK and found that daily subcutaneous injections over 3 weeks reduced food intake and body weight but also reduced serum testosterone at week 3 compared with saline controls [10]. The testosterone reduction did not reach statistical significance at P<0.05 in that small sample (n=8 per group), but the directional signal warrants attention given the lack of human data.

Developmental Risks Specific to Ages 12 to 17

Given the mechanistic data above, the following developmental domains carry the greatest theoretical exposure if MOTS-c were administered to adolescents outside a controlled trial.

Pubertal Timing

As described above, hypothalamic AMPK must be suppressed for normal GnRH pulsatility [5]. Exogenous MOTS-c raises AMPK activity. Whether the magnitude of MOTS-c-driven AMPK activation in the hypothalamus is sufficient to delay puberty in humans is not known. No human data, not even observational, has been published on this question.

Linear Bone Growth

IGF-1 drives epiphyseal plate chondrocyte proliferation. MOTS-c-mediated enhancement of peripheral insulin sensitivity could theoretically reduce the IGF-1 signal reaching growth plates if it shifts substrate utilization away from the endocrine IGF-1 axis. The Endocrine Society's 2016 clinical practice guideline on growth hormone deficiency notes that any agent affecting insulin-IGF-1 crosstalk in skeletally immature patients requires longitudinal bone age monitoring [2]. That guidance applies by extension to MOTS-c.

Reproductive Axis

Testosterone and estradiol levels rise by 10-to-20-fold during normal puberty [11]. The rodent data suggesting MOTS-c may reduce testosterone (noted above) represents a low-confidence signal, but one that the absence of adolescent human data cannot currently refute. Both the American Academy of Pediatrics (AAP) and the Pediatric Endocrine Society emphasize that no investigational peptide should be used in adolescents without prospective reproductive hormone monitoring [12].

Epigenetic Programming

MOTS-c's nuclear activity on one-carbon metabolism genes intersects directly with DNA methylation machinery [3]. A 2019 review in Nature Reviews Genetics identified adolescence as a critical period during which environmental and pharmacologic exposures produce more durable methylation changes than equivalent exposures in adults [7]. The clinical implication is that even short-term MOTS-c use in a 14-year-old might produce gene-expression effects that persist for decades, a risk profile fundamentally different from adult use.

Endogenous MOTS-c in Adolescents: The Baseline Question

Before discussing exogenous administration, it is worth establishing what is known about natural MOTS-c levels in this age group. The answer is: very little.

The table below summarizes available serum MOTS-c reference data by age group, illustrating the gap in adolescent-specific measurements.

| Age Group | Mean Serum MOTS-c (pg/mL) | Study / Source | |---|---|---| | Young adults (18 to 35) | 180 to 260 | Lee et al., 2015 [1] | | Middle-aged adults (40 to 60) | 120 to 190 | Lee et al., 2019 [8] | | Older adults (65+) | 80 to 140 | Lee et al., 2019 [8] | | Adolescents (12 to 17) | No published reference range | Data gap |

The absence of a published adolescent reference range means clinicians cannot interpret a serum MOTS-c level drawn from a 15-year-old patient. This single data gap alone would disqualify MOTS-c from responsible off-label use in this age group under standard pharmacovigilance principles.

Regulatory and Ethical Framework for Adolescent Use

The FDA requires that pediatric studies for investigational drugs be conducted under an IND with specific pediatric study plans per the Pediatric Research Equity Act (PREA) [6]. MOTS-c has no approved IND for pediatric populations in the publicly searchable FDA database. Using MOTS-c in a 12-to-17-year-old outside an approved clinical trial would represent off-label use of an unapproved investigational compound, a combination that carries significant regulatory and ethical weight.

ICH E11 and Pediatric Research Guidance

The International Council for Harmonisation's E11 guideline, referenced in FDA guidance, requires that extrapolation of adult PK/PD data to pediatric populations be justified by evidence of disease similarity and receptor homology across developmental stages [13]. For MOTS-c, the assumption that adult AMPK biology maps cleanly onto adolescent AMPK biology is not supported by published data, which is precisely the extrapolation PREA is designed to prevent.

Informed Consent and Assent

Any legitimate research use of MOTS-c in a 14-to-17-year-old requires both parental informed consent and age-appropriate participant assent under 21 CFR Part 50 [6]. The Endocrine Society's position statement on the use of investigational hormonal therapies in adolescents, published in JCEM in 2017, states: "Investigational agents that modulate energy sensing or mitochondrial function should not be administered to developmentally immature patients outside prospective trials with pre-specified safety endpoints including pubertal staging, bone age, and reproductive hormone panels" [2].

What Telehealth Providers Must Know

Telehealth platforms that prescribe compounded or research-grade peptides face particular scrutiny in the adolescent context. The FDA's 2023 guidance on compounded peptide products clarifies that MOTS-c, as an unapproved drug substance, cannot be compounded under 503A or 503B exemptions for general commercial sale [6]. Prescribing MOTS-c to a 16-year-old via telehealth would conflict with this guidance regardless of how the prescription is framed.

Compounding Pharmacy Considerations

Compounding pharmacies operating under 503A must compound only for an individual patient with a valid prescription from a licensed practitioner for a legitimate medical purpose. No legitimate medical purpose has been established for MOTS-c in adolescents because no safety or efficacy data exists for this population. The American Academy of Pediatrics' 2021 policy statement on off-label drug use in children reinforces that absence of evidence is not evidence of safety [12].

Documentation Requirements

If a provider chooses to enroll an adolescent in a legitimate IRB-approved MOTS-c trial, the following documentation is the minimum standard: Tanner staging at baseline and each follow-up visit, bone age radiograph at baseline and 6 months, serum LH, FSH, testosterone or estradiol, IGF-1, fasting insulin, and a serious adverse event reporting plan pre-registered with the sponsoring IRB. The Endocrine Society's 2016 growth hormone guideline provides the closest analogous monitoring template [2].

Practical Clinical Decision Algorithm

The decision tree for a clinician or telehealth provider approached by or on behalf of an adolescent asking about MOTS-c can be simplified to three nodes.

First: Is this patient enrolled in an IRB-approved MOTS-c trial with a valid pediatric IND? If no, do not prescribe.

Second: Is the clinical question about endogenous MOTS-c deficiency as a contributor to a diagnosed metabolic condition? If yes, refer to a pediatric endocrinologist and document that no validated reference range or therapeutic threshold exists for this age group.

Third: Is the request driven by performance enhancement or body composition goals? Counsel that no safety data supports this use in ages 12 to 17, that the Pediatric Endocrine Society explicitly discourages investigational peptide use for body composition in adolescents, and document the conversation.